APA (7th ed.) Citation

Fomin, V., Buckholz, A., Liu, Y., Mallick, H., & Kumar, S. (2024). SAT-251 Semaglutide can reduce alcohol use in patients with metabolic dysfunction-associated steatotic liver disease. Journal of Hepatology, 80, S138. https://doi.org/10.1016/S0168-8278(24)00700-1

Chicago Style (17th ed.) Citation

Fomin, Vladislav, Adam Buckholz, Yihan Liu, Himel Mallick, and Sonal Kumar. "SAT-251 Semaglutide Can Reduce Alcohol Use in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease." Journal of Hepatology 80 (2024): S138. https://doi.org/10.1016/S0168-8278(24)00700-1.

MLA (9th ed.) Citation

Fomin, Vladislav, et al. "SAT-251 Semaglutide Can Reduce Alcohol Use in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease." Journal of Hepatology, vol. 80, 2024, p. S138, https://doi.org/10.1016/S0168-8278(24)00700-1.